{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:36:51Z","timestamp":1787971011036,"version":"build-2784847793"},"reference-count":117,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/19374-9; 2018\/13877-1;2018\/12149-2"],"award-info":[{"award-number":["2017\/19374-9; 2018\/13877-1;2018\/12149-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["303373\/2019-9"],"award-info":[{"award-number":["303373\/2019-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Cryptococcosis is an important opportunistic infection and a leading cause of meningitis in patients with HIV infection. The antifungal pharmacological treatment is limited to amphotericin B, fluconazole and 5- flucytosine. In addition to the limited pharmacological options, the high toxicity, increased resistance rate and difficulty of the currently available antifungal molecules to cross the blood\u2013brain barrier hamper the treatment. Thus, the search for new alternatives for the treatment of cryptococcal meningitis is extremely necessary. In this review, we describe the therapeutic strategies currently available, discuss new molecules with antifungal potential in different phases of clinical trials and in advanced pre-clinical phase, and examine drug nanocarriers to improve delivery to the central nervous system.<\/jats:p>","DOI":"10.3390\/microorganisms8040613","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T11:42:14Z","timestamp":1587728534000},"page":"613","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["New Approaches for Cryptococcosis Treatment"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7486-5742","authenticated-orcid":false,"given":"Cristina de Castro","family":"Spadari","sequence":"first","affiliation":[{"name":"Laboratory of Antifungal Chemotherapy, Department of Microbiology, Institute of Biomedical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Wirth","sequence":"additional","affiliation":[{"name":"Laboratory of Antifungal Chemotherapy, Department of Microbiology, Institute of Biomedical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Biagini","family":"Lopes","sequence":"additional","affiliation":[{"name":"Laboratory of Nanomedicine and Drug Delivery Systems, Department of Pharmacology, Institute of Biomedical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4602-0926","authenticated-orcid":false,"given":"Kelly","family":"Ishida","sequence":"additional","affiliation":[{"name":"Laboratory of Antifungal Chemotherapy, Department of Microbiology, Institute of Biomedical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.idc.2015.10.006","article-title":"Cryptococcosis","volume":"30","author":"Maziarz","year":"2016","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrmicro.2015.6","article-title":"Cryptococcus: From environmental saprophyte to global pathogen","volume":"14","author":"May","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev.micro.60.080805.142102","article-title":"The biology of the Cryptococcus neoformans species complex","volume":"60","author":"Lin","year":"2006","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/CMR.00001-12","article-title":"The Cryptococcus neoformans capsule: A sword and a shield","volume":"25","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: An updated analysis","volume":"17","author":"Rajasingham","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","first-page":"1","article-title":"Fungal infections in HIV\/AIDS","volume":"3099","author":"Limper","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1473-3099(13)70078-1","article-title":"Cryptococcal meningitis: Improving access to essential antifungal medicines in resource-poor countries","volume":"13","author":"Loyse","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1473-3099(18)30493-6","article-title":"Leave no one behind: Response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries","volume":"19","author":"Loyse","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","unstructured":"World Health Organization (2019, February 20). Guidelines for the Diagnosis, Prevention, and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children. Available online: https:\/\/www.who.int\/hiv\/pub\/guidelines\/cryptococcal-disease\/en\/."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/13693786.2012.715763","article-title":"Fluconazole resistance in cryptococcal disease: Emerging or intrinsic?","volume":"51","author":"Cheong","year":"2013","journal-title":"Med. Mycol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/myc.12747","article-title":"A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species","volume":"61","author":"Bongomin","year":"2018","journal-title":"Mycoses"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/mmy\/myx054","article-title":"Relationship between intracranial pressure and antifungal agents levels in the CSF of patients with cryptococcal meningitis","volume":"56","author":"Wirth","year":"2018","journal-title":"Med. Mycol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/17425255.3.4.573","article-title":"CNS pharmacokinetics of antifungal agents","volume":"3","author":"Kethireddy","year":"2007","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/mi.3.2.90","article-title":"Blood-brain barrier drug Targeting: The future of brain drug development","volume":"3","author":"Pardridge","year":"2003","journal-title":"Mol. Interv."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ashley, E.D. (2019). Antifungal Drugs: Special problems treating Central Nervous System infections. J. Fungi, 5.","DOI":"10.3390\/jof5040097"},{"key":"ref_17","unstructured":"World Health Organization (2018). Guidelines for the Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection, World Health Organization."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.fgb.2014.10.003","article-title":"Cryptococcosis diagnosis and treatment: What do we know now","volume":"78","author":"Perfect","year":"2015","journal-title":"Fungal Genet. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/49.suppl_1.7","article-title":"Amphotericin B: Spectrum and resistance","volume":"49","author":"Ellis","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8488","DOI":"10.1021\/ja403255s","article-title":"C2\u2032-OH of Amphotericin B plays an important role in binding the primary sterol of human cells but not yeast cells","volume":"135","author":"Wilcock","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"ref_21","first-page":"1","article-title":"Design of amphotericin B oral formulation for antifungal therapy","volume":"24","author":"Liu","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Cuddihy, G., Wasan, E.K., Di, Y., and Wasan, K.M. (2019). The development of oral amphotericin B to treat systemic fungal and parasitic infections: Has the myth been finally realized?. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11030099"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: Practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"ref_24","unstructured":"Lozano-Chiu, M., and Rex, J.H. (1998). Resistance to antifungal agents. Topley & Wilson\u2019s Microbiology and Microbial Infections, Arnold. [9th ed.]."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1093\/mmy\/myx119","article-title":"Aspergillus terreus: Novel lessons learned on amphotericin B resistance","volume":"56","author":"Posch","year":"2018","journal-title":"Med. Mycol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"O\u2019Shaughnessy, E.M., Lyman, C.A., and Walsh, T.J. (2009). Amphotericin B: Polyene resistance mechanisms. Antimicrobial Drug Resistance, Humana Press.","DOI":"10.1007\/978-1-59745-180-2_25"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/ja01573a087","article-title":"The synthesis of 5-Fluoropyrimidines","volume":"79","author":"Duschinsky","year":"1957","journal-title":"J. Am. Chem. Soc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jama.1968.03150040042009","article-title":"Treatment of Candida sepsis and Cryptococcus meningitis with 5-Fluorocytosine","volume":"206","author":"Tassel","year":"1968","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000221854","article-title":"Mode of action of 5-Fluorocytosine and mechanisms of resistance","volume":"21","author":"Polak","year":"1975","journal-title":"Chemotherapy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/AAC.2.3.114","article-title":"In Vitro studies of 5-Fluorocytosine resistance in Candida albicans and Torulopsis glabrata","volume":"2","author":"Normark","year":"1972","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2011.11.001","article-title":"Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment","volume":"125","author":"Pfaller","year":"2012","journal-title":"Am. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/1120009X.1990.11738981","article-title":"The discovery and profile of Fluconazole","volume":"2","author":"Richardson","year":"1990","journal-title":"J. Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/infdis\/173.5.1216","article-title":"Treatment of experimental Cryptococcal meningitis with Fluconazole: Impact of dose and addition of Flucytosine on mycologic and pathophysiologic outcome","volume":"173","author":"Kartalija","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1093\/clinids\/12.Supplement_3.S318","article-title":"Pharmacokinetics and tissue penetration of Fluconazole in humans","volume":"12","author":"Brammer","year":"1990","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2165\/00003495-199550040-00007","article-title":"Fluconazole","volume":"50","author":"Goa","year":"1995","journal-title":"Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/myc.12543","article-title":"Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain","volume":"60","author":"Gago","year":"2017","journal-title":"Mycoses"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1128\/AAC.47.11.3653-3656.2003","article-title":"G484S amino acid substitution in Lanosterol 14-\u03b1 Demethylase (ERG11) is related to Fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate","volume":"47","author":"Rodero","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1128\/AAC.00295-09","article-title":"Heteroresistance to Fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence","volume":"53","author":"Sionov","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2165\/00003495-200464180-00001","article-title":"Newer systemic antifungal agents","volume":"64","author":"Boucher","year":"2004","journal-title":"Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/Pharmacodynamic profile of Voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1128\/AAC.43.8.1856","article-title":"Heteroresistance to Fluconazole and Voriconazole in Cryptococcus neoformans","volume":"43","author":"Mondon","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1179\/joc.2011.23.6.379","article-title":"A case of Fluconazole, Voriconazole-resistant Cryptococcus neoformans isolated from an immunocompetent patient","volume":"23","author":"Mandras","year":"2011","journal-title":"J. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/jac\/dki393","article-title":"Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans","volume":"56","author":"Perkins","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/mmy\/myw101","article-title":"Multi-azole-resistant strains of Cryptococcus neoformans var. grubii isolated from a FLZ-resistant strain by culturing in medium containing voriconazole","volume":"55","author":"Kano","year":"2017","journal-title":"Med. Mycol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3892\/ol.2017.6325","article-title":"Repurposing itraconazole as an anticancer agent","volume":"14","author":"Tsubamoto","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e4761","DOI":"10.7717\/peerj.4761","article-title":"Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis","volume":"6","author":"Truong","year":"2018","journal-title":"PeerJ"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1086\/420829","article-title":"Recombinant Interferon-\u03b31b as adjunctive therapy for AIDS-related acute Cryptococcal meningitis","volume":"189","author":"Pappas","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_49","first-page":"123","article-title":"Contribution of interferon-\u03b3 in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans","volume":"13","author":"Kawakami","year":"1996","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/QAD.0b013e3283536a93","article-title":"Adjunctive interferon-\u03b3 immunotherapy for the treatment of HIV-associated cryptococcal meningitis","volume":"26","author":"Jarvis","year":"2012","journal-title":"AIDS"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1128\/AAC.47.7.2208-2216.2003","article-title":"Preclinical assessment of the efficacy of Mycograb, a human recombinant antibody against fungal HSP90","volume":"47","author":"Matthews","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1099\/mic.0.000222","article-title":"Inhibition of heat-shock protein 90 enhances the susceptibility to antifungals and reduces the virulence of Cryptococcus neoformans\/Cryptococcus gattii species complex","volume":"162","author":"Serpa","year":"2016","journal-title":"Microbiology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.diagmicrobio.2004.08.013","article-title":"Evaluation of Mycograb\u00ae, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies","volume":"51","author":"Nooney","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1128\/AAC.42.6.1437","article-title":"Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies","volume":"42","author":"Casadevall","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1128\/AAC.39.7.1398","article-title":"Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy","volume":"39","author":"Mukherjee","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/jac\/37.3.617","article-title":"Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro","volume":"37","author":"Feldmesser","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/infdis\/163.5.1114","article-title":"Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: Study during murine Cryptococcosis and mechanisms of action","volume":"163","author":"Dromer","year":"1991","journal-title":"J. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4049\/jimmunol.158.2.790","article-title":"Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection","volume":"158","author":"Feldmesser","year":"1997","journal-title":"J. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1128\/AAC.49.3.952-958.2005","article-title":"Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated Cryptococcal meningitis","volume":"49","author":"Larsen","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zhao, M., Lepak, A.J., Marchillo, K., Vanhecker, J., Sanchez, H., Ambrose, P.G., and Andes, D.R. (2019). APX001 Pharmacokinetic\/Pharmacodynamic target determination against Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.02372-18"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Pfaller, M.A., Huband, M.D., Flamm, R.K., Bien, P.A., and Castanheira, M. (2019). In Vitro activity of APX001A (Manogepix) and comparator agents against 1,706 fungal isolates collected during an International Surveillance Program (2017). Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00840-19"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Shaw, K.J., Schell, W.A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q.A., Tenor, J.L., and Toffaletti, D.L. (2018). In Vitro and In Vivo evaluation of APX001A\/APX001 and other Gwt1 inhibitors against Cryptococcus. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.00523-18"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1128\/AAC.05954-11","article-title":"T-2307 causes collapse of mitochondrial membrane potential in yeast","volume":"56","author":"Shibata","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.01159-07","article-title":"In Vitro and In Vivo antifungal activities of T-2307, a novel arylamidine","volume":"52","author":"Mitsuyama","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/jac\/dkx020","article-title":"In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: An emerging fungal pathogen","volume":"72","author":"Nishikawa","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003088-200241150-00002","article-title":"Clinical pharmacokinetics of Sertraline","volume":"41","author":"DeVane","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1128\/AAC.00212-12","article-title":"The Antidepressant Sertraline provides a promising therapeutic option for neurotropic Cryptococcal infections","volume":"56","author":"Zhai","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/mmy\/myv109","article-title":"Activity of sertraline against Cryptococcus neoformans: In vitro and in vivo assays","volume":"54","year":"2016","journal-title":"Med. Mycol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/21501203.2010.487054","article-title":"Effects of sertraline hydrochloride and fluconazole combinations on Cryptococcus neoformans and Cryptococcus gattii","volume":"1","author":"Nayak","year":"2010","journal-title":"Mycology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/msb.2011.31","article-title":"Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole","volume":"7","author":"Spitzer","year":"2011","journal-title":"Mol. Syst. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1473-3099(19)30127-6","article-title":"Adjunctive sertraline for HIV-associated cryptococcal meningitis: A randomised, placebo-controlled, double-blind phase 3 trial","volume":"19","author":"Rhein","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-200342040-00004","article-title":"Pharmacokinetics of selective estrogen receptor modulators","volume":"42","author":"Morello","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/myc.12955","article-title":"The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans","volume":"62","author":"Hai","year":"2019","journal-title":"Mycoses"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Butts, A., Koselny, K., Chabrier-Rosell\u00f3, Y., Semighini, C.P., Brown, J.C.S., Wang, X., Annadurai, S., DiDone, L., Tabroff, J., and Childers, W.E. (2014). Estrogen receptor antagonists are anti-Cryptococcal agents that directly bind EF Hand proteins and synergize with Fluconazole In Vivo. MBio, 5.","DOI":"10.1128\/mBio.00765-13"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/13543776.2018.1503252","article-title":"Future perspectives for cryptococcosis treatment","volume":"28","author":"Rodrigues","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1021\/acsinfecdis.5b00134","article-title":"Antitumor\/Antifungal celecoxib derivative AR-12 is a non-nucleoside inhibitor of the ANL-family adenylating enzyme Acetyl CoA synthetase","volume":"2","author":"Koselny","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7115","DOI":"10.1128\/AAC.01061-16","article-title":"The celecoxib derivative AR-12 has broad-spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of cryptococcosis","volume":"60","author":"Koselny","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14656566.2015.973850","article-title":"An update on pharmacotherapy for leishmaniasis","volume":"16","author":"Sundar","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1016\/j.bmcl.2013.06.096","article-title":"Synthesis and antifungal activities of miltefosine analogs","volume":"23","author":"Ravu","year":"2013","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.50.2.414-421.2006","article-title":"Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis","volume":"50","author":"Widmer","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00312-18","article-title":"Miltefosine has a postantifungal effect and induces apoptosis in Cryptococcus yeasts","volume":"62","author":"Spadari","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.2147\/IJN.S205350","article-title":"Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis","volume":"14","author":"Spadari","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1128\/AAC.01624-12","article-title":"Limited activity of Miltefosine in murine models of Cryptococcal meningoencephalitis and disseminated Cryptococcosis","volume":"57","author":"Wiederhold","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bmcl.2017.12.040","article-title":"Design, synthesis, and structure-activity relationship studies of novel tetrazole antifungal agents with potent activity, broad antifungal spectrum and high selectivity","volume":"28","author":"Qian","year":"2018","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejmech.2019.03.023","article-title":"Tetrazole hybrids and their antifungal activities","volume":"170","author":"Wang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijantimicag.2017.09.002","article-title":"The antifungal arsenal: Alternative drugs and future targets","volume":"51","author":"Wiederhold","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd.2017.46","article-title":"The antifungal pipeline: A reality check","volume":"16","author":"Perfect","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1128\/AAC.02770-15","article-title":"Potent In Vitro activity against Cryptococcus neoformans and Cryptococcus gattii","volume":"60","author":"Lockhart","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_89","first-page":"453","article-title":"Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs","volume":"55","author":"Nielsen","year":"2017","journal-title":"Med. Mycol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/jac\/dkx410","article-title":"Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1093\/jac\/dky242","article-title":"The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis","volume":"73","author":"Garvey","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Rossi, S.A., de Oliveira, H.C., Agreda-Mellon, D., Lucio, J., Mendes Giannini, M.J.S., Garc\u00eda-Cambero, J.P., and Zaragoza, O. (2020). Identification of off-patent drugs that show synergism with Amphotericin B or that present antifungal action against Cryptococcus neoformans and Candida spp.. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.01921-19"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2017.00535","article-title":"The anti-helminthic compound mebendazole has multiple antifungal effects against Cryptococcus neoformans","volume":"8","author":"Joffe","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Nixon, G.L., McEntee, L., Johnson, A., Farrington, N., Whalley, S., Livermore, J., Natal, C., Washbourn, G., Bibby, J., and Berry, N. (2018). Repurposing and reformulation of the antiparasitic agent flubendazole for treatment of Cryptococcal meningoencephalitis, a neglected fungal disease. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.01909-17"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1086\/319272","article-title":"Glyphosate inhibits melanization of Cryptococcus neoformans and prolongs survival of mice after systemic Infection","volume":"183","author":"Nosanchuk","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1128\/EC.00370-07","article-title":"Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence","volume":"7","author":"Rodrigues","year":"2008","journal-title":"Eukaryot. Cell"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Mor, V., Rella, A., Farnoud, A.M., Singh, A., Munshi, M., Bryan, A., Naseem, S., Konopka, J.B., Ojima, I., and Bullesbach, E. (2015). Identification of a new class of antifungals targeting the synthesis of fungal sphingolipids. MBio, 6.","DOI":"10.1128\/mBio.00647-15"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2011.08.017","article-title":"Transport of drugs across the blood\u2013brain barrier by nanoparticles","volume":"161","author":"Wohlfart","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_99","first-page":"1","article-title":"Nanopharmaceuticals: A boon to the brain-targeted drug delivery","volume":"Volume I","author":"Zeeshan","year":"2020","journal-title":"Pharmaceutical Formulation Design\u2014Recent Practices"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","article-title":"Crossing the blood\u2013brain barrier with nanoparticles","volume":"270","author":"Zhou","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ajps.2018.09.005","article-title":"Nanocarriers as a powerful vehicle to overcome blood\u2013brain barrier in treating neurodegenerative diseases: Focus on recent advances","volume":"14","author":"Niu","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.addr.2008.08.002","article-title":"Hydrogel nanoparticles in drug delivery","volume":"60","author":"Hamidi","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2174\/1389201015666140508122558","article-title":"V Nanoparticle enabled drug delivery across the blood brain barrier: In vivo and in vitro models, opportunities and challenges","volume":"14","author":"Gidwani","year":"2014","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijpharm.2005.03.031","article-title":"Colloidal carriers and blood\u2013brain barrier (BBB) translocation: A way to deliver drugs to the brain?","volume":"298","author":"Andrieux","year":"2005","journal-title":"Int. J. Pharm."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1021\/mp900191s","article-title":"Vitamin E TPGS P-Glycoprotein inhibition mechanism: Influence on conformational flexibility, intracellular ATP levels, and role of time and site of access","volume":"7","author":"Collnot","year":"2010","journal-title":"Mol. Pharm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.addr.2012.09.015","article-title":"Nanoparticulate systems for brain delivery of drugs","volume":"64","author":"Kreuter","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/AAC.44.9.2356-2360.2000","article-title":"Efficacy of oral cochleate-Amphotericin B in a mouse model of systemic Candidiasis","volume":"44","author":"Santangelo","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Lu, R., Hollingsworth, C., Qiu, J., Wang, A., Hughes, E., Xin, X., Konrath, K.M., Elsegeiny, W., Park, Y.-D., and Atakulu, L. (2019). Efficacy of oral encochleated Amphotericin B in a mouse model of Cryptococcal meningoencephalitis. MBio, 10.","DOI":"10.1128\/mBio.00724-19"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1163\/092050609X12457418779185","article-title":"Preparation and therapeutic efficacy of polysorbate-80-coated Amphotericin B\/PLA-b-PEG Nanoparticles","volume":"20","author":"Ren","year":"2009","journal-title":"J. Biomater. Sci. Polym."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/IJN.S17503","article-title":"Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice","volume":"6","author":"Xu","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jconrel.2010.06.018","article-title":"Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain","volume":"147","author":"Shao","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.1016\/j.biomaterials.2012.06.050","article-title":"A brain-vectored angiopep-2 based polymeric micelles for the treatment of intracranial fungal infection","volume":"33","author":"Shao","year":"2012","journal-title":"Biomaterials"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejps.2015.07.010","article-title":"Development and lyophilization of itraconazole loaded poly(butyl cyanoacrylate) nanospheres as a drug delivery system","volume":"78","author":"Keller","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejpb.2017.01.014","article-title":"Development and characterization of novel highly-loaded itraconazole poly(butyl cyanoacrylate) polymeric nanoparticles","volume":"114","author":"Fricker","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"119002","DOI":"10.1016\/j.ijpharm.2019.119002","article-title":"Borneol and poly (ethylene glycol) dual modified BSA nanoparticles as an itraconazole vehicle for brain targeting","volume":"575","author":"Zhang","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/10717544.2017.1346002","article-title":"Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood\u2013brain barrier permeability","volume":"24","author":"Zhang","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3109\/1061186X.2010.492523","article-title":"Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles","volume":"19","author":"Chen","year":"2011","journal-title":"J. Drug Target."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/8\/4\/613\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:45:23Z","timestamp":1760363123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/8\/4\/613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":117,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["microorganisms8040613"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms8040613","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]}}}